Beta-Blocker Therapy for Toxic Catecholamine Syndrome
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Critically ill patients, such as those suffering from trauma, sepsis, and out-of-hospital cardiac arrest, face high early mortality rates due to unmanaged toxic hyperactivation of the sympathetic nervous system, leading to excessive catecholamine levels and hemodynamic instability, for which current treatments are inadequate.
Innovation Solution
Identifying patients with elevated succinic acid levels, indicative of Toxic Catecholamine Syndrome, and administering a medicament that inhibits catecholamine release or blocks adrenergic receptors, typically beta-blockers, to mitigate toxic catecholamine effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If beta-blockers are used to block adrenergic receptors, then toxic catecholamine effects are mitigated, but traditional contraindication in critically ill subjects increases risk
Solution Approach 1:
The invention changes the parameter of catecholamine levels by using beta-blockers to reduce toxic catecholamine effects. The patent identifies patients with elevated succinic acid levels as candidates for this treatment, thereby changing the clinical parameter from conventional treatment protocols to a targeted approach based on biomarker identification.
Solution Approach 2:
The invention implements feedback by measuring succinic acid levels in patients to determine eligibility for beta-blocker treatment. This feedback mechanism allows for personalized treatment decisions, where patients with elevated succinic acid levels (indicating toxic catecholamine syndrome) are identified and targeted for specific therapy, while others receive conventional treatment.
2Reliability
If conventional treatment protocols are followed for critically ill patients, then standard care is provided, but early mortality remains high
Solution Approach 1:
The invention segments the critically ill patient population into two groups based on succinic acid levels: patients with elevated levels (indicating toxic catecholamine syndrome) and patients with normal levels. This segmentation allows for differentiated treatment strategies, where beta-blockers are applied selectively to the high-risk group, thereby improving overall survival rates while maintaining standard care quality for the general population.
Solution Approach 2:
The invention applies local quality by tailoring treatment approaches to specific patient subgroups. Instead of uniform treatment for all critically ill patients, the patent implements localized intervention (beta-blocker therapy) for patients with elevated succinic acid levels, while conventional treatment continues for others. This localized approach optimizes treatment effectiveness for high-risk patients without compromising overall standard care.
Data Source
AI summary
The present invention relates to a medicament for treatment of critically ill subjects with elevated levels of succinic acid, and a method of identifying patients likely to benefit from treatment with a medicament capable of inhibiting catecholamine release and/or blocking adrenergic receptors.